Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1D11.16
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraarticular, Intraperitoneal, Intratumoral, Intravenous, Subcutaneous
01
Overview
1D11.16 (often referred to simply as 1D11) is a murine IgG1 monoclonal antibody that acts as a pan-specific neutralizer of all three mammalian isoforms of transforming growth factor-beta (TGF-β1, TGF-β2, and TGF-β3). Originally developed by Genzyme, 1D11.16 is widely utilized as a preclinical research tool and therapeutic candidate in animal models of cancer, fibrosis, and inflammation. By binding and neutralizing active TGF-β, the antibody blocks downstream Smad signaling, thereby reversing TGF-β-mediated immunosuppression, inhibiting fibrogenesis, and enhancing the efficacy of radiotherapy and cancer vaccines. It served as the parent antibody for the development of the humanized clinical candidate fresolimumab (GC1008).
- Other names
- anti-TGF-beta monoclonal antibody 1D11.16clone 1D11.16clone1D11.16clone-1D11.16clone 1D11.16.8clone1D11.16.8clone-1D11.16.8pan-specific TGF-beta neutralizing antibody 1D11.16
02
Targets
TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on 1D11.16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1D11.16.